Psychiatry's Biggest Mistake? | Dr Kris Kaliebe
28 May 2026
With Dr. Kristopher Kaliebe
Global
Psychiatry professor Dr. Kristopher Kaliebe examines how a shift from psychoanalytic to biological frameworks, accelerated by pharmaceutical industry influence, has shaped the clinical response to gender dysphoria in young people. His analysis connects directly to a pattern European evidence reviews have independently identified: systematic reviews in the UK, Sweden, Finland and Denmark found the research base for paediatric medical transition methodologically weak, and national guideline revisions have reoriented care toward psychological assessment. The conversation also addresses the US HHS evidence report and the emerging clinical concept of extreme overvalued belief.
Dr. Kristopher Kaliebe is a Professor of Psychiatry at the University of South Florida with board certifications in general, child and adolescent, and forensic psychiatry. His clinical and academic standing gives unusual weight to an episode that examines psychiatry from within — as a discipline that has made consequential institutional errors before and may be repeating the pattern in its response to gender dysphoria in young people. The conversation traces how psychiatry moved from psychoanalytic to biological frameworks over several decades. That shift brought genuine advances but also cultivated a tendency to reduce complex psychological suffering to simple causal narratives. The chemical imbalance theory of depression is the most familiar case — a shorthand that solidified into clinical doctrine and shaped prescribing for a generation before the evidence base caught up with it. Kaliebe argues that the 'born in the wrong body' account of gender dysphoria has followed the same trajectory: a metaphor adopted by clinicians, patients and institutions as literal biological fact, generating a treatment pathway whose evidential foundations were never rigorously established. Pharmaceutical industry influence, overdiagnosis and professional agreeableness are examined as compounding factors. When distress is reframed as innate biology, the threshold for medical intervention falls and critical appraisal weakens. Kaliebe connects this dynamic to the rapid rise in young people presenting with gender dysphoria, noting that an affirmation-only clinical posture displaced the diagnostic thoroughness the evidence requires. This is not an observation confined to any single country. It is precisely the pattern that prompted systematic evidence reviews in the United Kingdom, Sweden, Finland, Denmark and Norway between 2020 and 2024, each of which resulted in significant restrictions on paediatric medical transition. The episode examines the concept of extreme overvalued belief as a clinical framework better suited to certain presentations of adolescent gender dysphoria — particularly those emerging rapidly and in the context of social influence. The HHS evidence report is discussed as a document that formally evaluated the research base and found the evidence for paediatric medical transition to be weak and methodologically compromised. That conclusion aligns closely with what European systematic reviews, including those commissioned by the NHS in England, had independently reached. The closing question — whether psychiatry should repathologise gender dysphoria, treating it as a condition requiring thorough psychological assessment rather than an identity warranting automatic affirmation — is examined seriously rather than resolved. Kaliebe's position is not a call for a return to historical practice but a demand for the clinical rigour that has been displaced. Several European countries have already moved in that direction through updated national guidelines requiring co-occurring mental health conditions to be assessed before any medical pathway is considered, placing the European evidence record ahead of wider institutional acknowledgement.
